Nonetheless, there are ongoing clinical trials investigating the use of vanucizumab in combination with atezolizumab (anti‐PD‐L1) or CD40 agonists (Table 2), although atezolizumab plus vanucizumab has thus far not shown significant benefit over the monotherapies in platinum‐resistant recurrent ovarian cancer (Oaknin et al,2017) (Table 2). Here, CD40 is linked to ovarian cancer.